(Q39158102)

9 September 2017

Cobicistat (GS-9350): A Potent and Selective Inhibitor of Human CYP3A as a Novel Pharmacoenhancer (English)

1 reference

9 September 2017

1 reference

Allen Hong

6

0 references

author name string

Lianhong Xu

1

1 reference

9 September 2017

Hongtao Liu

2

1 reference

9 September 2017

Bernard P Murray

3

1 reference

9 September 2017

Christian Callebaut

4

1 reference

9 September 2017

Melody S Lee

5

1 reference

9 September 2017

Robert G Strickley

7

1 reference

9 September 2017

Luong K Tsai

8

1 reference

9 September 2017

Kirsten M Stray

9

1 reference

9 September 2017

Yujin Wang

10

1 reference

9 September 2017

Gerry R Rhodes

11

1 reference

9 September 2017

Manoj C Desai

12

1 reference

9 September 2017

17 May 2010

1 reference

ACS Medicinal Chemistry Letters

9 September 2017

1 reference

9 September 2017

1

1 reference

9 September 2017

5

1 reference

9 September 2017

209-213

1 reference

Pharmacokinetic enhancers for HIV drugs.

9 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Better adherence with once-daily antiretroviral regimens: a meta-analysis

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Increased regimen durability in the era of once-daily fixed-dose combination antiretroviral therapy

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society-USA panel

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Induction effects of ritonavir: implications for drug interactions

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Cytochrome p450 turnover: regulation of synthesis and degradation, methods for determining rates, and implications for the prediction of drug interactions

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavir

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Overview of boosted protease inhibitors in treatment-experienced HIV-infected patients

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Does atazanavir cause lipodystrophy?

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

A review of low-dose ritonavir in protease inhibitor combination therapy

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Using pharmacokinetics to optimize antiretroviral drug-drug interactions in the treatment of human immunodeficiency virus infection

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir.

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

ABT-538 is a potent inhibitor of human immunodeficiency virus protease and has high oral bioavailability in humans

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

A novel probe drug interaction study to investigate the effect of selected antiretroviral combinations on the pharmacokinetics of a single oral dose of maraviroc in HIV-positive subjects

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Pharmacokinetics and pharmacodynamics of GS-9350: a novel pharmacokinetic enhancer without anti-HIV activity

10 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Pharmacokinetic interaction of ritonavir-boosted elvitegravir and maraviroc

17 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Dose-response of ritonavir on hepatic CYP3A activity and elvitegravir oral exposure

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Mechanism-based inactivation of CYP3A by HIV protease inhibitors

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

21 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4007915

Potent mechanism-based inhibition of human CYP3A in vitro by amprenavir and ritonavir: comparison with ketoconazole

21 August 2018

1 reference

12 December 2020

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

1 reference

12 December 2020

Mechanism-based inactivation of human cytochrome p450 enzymes and the prediction of drug-drug interactions

1 reference

12 December 2020

Drug interaction studies: study design, data analysis, and implications for dosing and labeling

1 reference

12 December 2020

Pharmacological enhancement of protease inhibitors with ritonavir: an update

1 reference

12 December 2020

Identifiers

DOI

10.1021/ML1000257

1 reference

9 September 2017

1 reference

9 September 2017

1 reference